Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
PARADIGM BIOPHARMACEUTICALS LIMITED (PAR)ASX AI Signals has generated 6 signals for PAR during the last 90 days, indicating strong trading activity and ongoing AI monitoring
Latest PAR Signals | |
| 09/06/2026 | SELL |
| 08/06/2026 | SELL |
| 07/06/2026 | SELL |
PAR Share Price | |
| Current Price | $0.175 |
| 52 Week High | $0.450 |
| 52 Week Low: | $0.140 |
| Trading at (% of 52 Week High) | 38.89% |
Paradigm Biopharmaceuticals Limited (ASX: PAR) is a biotechnology company focused on developing treatments for inflammatory and fibrotic diseases. The company’s main product candidate is a novel drug based on peptide technology aimed at addressing conditions such as osteoarthritis and lung fibrosis. Paradigm conducts research and clinical trials to advance its drug development programs.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The SELL recommendation for PARADIGM BIOPHARMACEUTICALS LIMITED is supported by weak price momentum and potential sector volatility. However, the relatively low current price and possible upcoming catalysts introduce some uncertainty, moderating the confidence level.
DelveInsight Business Research LLP
The osteoarthritis market is projected to grow from 2026 to 2036, driven by an aging population and rising disease prevalence. The expected launch of emerging therapies such as LEVI-04 (Levicept), ZILOSUL (Paradigm Biopharmaceuticals), TissueGene-C (TG-C) (Kolon T Paradigm Biopharma launches clinical trial website to support development program for knee osteoarthritis therapy.
MELBOURNE, Australia, May 25, 2023 /PRNewswire/ -- With the launch of a new website dedicated to their global clinical trials (https://hope4OA.com), Paradigm Biopharmaceuticals Ltd. (P Paradigm Biopharmaceuticals
Top-line phase 2 trial data shows disease modifying potential and pain reduction
MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Australia’s Paradigm Biopharmaceuticals Ltd (ASX:PAR) says analysis of six-month trial data shows injectable pentosan polysulfate so KEY HIGHLIGHTS
Primary endpoint relating to synovial fluid biomarkers achieved and positive top-line results reported for the PARA_OA_008 phase 2 clinical trial (n=61). Several osteoarthritis (OA) biomarkers analysed were observed to favourably change over time in patients treated with injectable P KEY HIGHLIGHTS
Paradigm has been invited to present results from the mucopolysaccharidosis (MPS) program, with an oral presentation at the XVII International Conference on Lysosomal Diseases (ICLD 2023), to be held in Sydney, Australia, February 20-21, 2023. Dr Drago Bratkovic, Head of the MetaboliLatest PARADIGM BIOPHARMACEUTICALS LIMITED(PAR) News
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
Hope for knee osteoarthritis sufferers with advent of global clinical trial.
Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up
Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial
MPS Clinical Program Update and Paradigm to Present at the International Conference on Lysosomal Diseases
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial